News | August 26, 2021
Strong show in domestic formulations business by Indian pharma in Q1FY22: Ind-Ra
Domestic business was up 41.9% YoY and 27.7% QoQ
Domestic business was up 41.9% YoY and 27.7% QoQ
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
The foundation has been working closely with the Kidwai Memorial Institute of Oncology on several projects since 2001
This year, the company plans to set up more than 200 labs and 3000 collection centres across the world and has ended FY 21 with a revenue of Rs 800 crores
BD worked with JCI to create a Gold Standard benchmarked safety program called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME)
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
As part of the PMGDisha-CoWIN integration, Mercer | Mettl has aggregated the database of 5 crore Aadhaar-authenticated and registered candidates, which is now being utilized to deliver vaccinations to the last mile populace
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
_256_384.jpg)
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
Subscribe To Our Newsletter & Stay Updated
